Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
Brett P. Monia(Ionis Pharmaceuticals (United States)), Doriano Fabbro(Novartis (Switzerland)), Thomas Geiger(Novartis (Switzerland)), Joseph F. Johnston(Ionis Pharmaceuticals (United States)), Marcel A. Müller(University of Bonn)
Cited by 453
Related Papers
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
|Nucleic Acids Research|2017|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k